Despite a Near-Term Decline, the Drug Market for Addiction Disorders Will Increase from Just under $2 Billion in 2010 to M

From 2015 to 2020, the Launch of Novel Agents from BioTie Therapies/Lundbeck and Titan Pharmaceuticals Will Drive Market Growth, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite a near-term decline in the overall size of the market, the drug market for addiction disorders (nicotine, alcohol, opioid and psychostimulants) will increase from just under $2 billion in 2010 to more than $2.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. From 2015 to 2020, the launch of novel therapies—most notably, BioTie Therapies/Lundbeck’s nalmefene for alcohol dependence and Titan Pharmaceuticals’ buprenorphine implant for opioid dependence—will drive market growth.

The Pharmacor report entitled Addiction Disorders finds that significant unmet need and opportunity will remain in the addiction disorders therapy market through 2020. Additionally, despite having the largest prevalent population among the addiction disorders under study, the market for alcohol addiction will represent only 13 percent of the total addiction space in 2020. According to interviewed experts, emerging agents will do little to address the dearth of effective therapies for alcohol addiction, particularly in the United States.

According to the report, factors constraining the addiction disorders market will include the potential launch of generic buprenorphine/naloxone sublingual tablets (Reckitt Benckiser Pharmaceuticals’ Suboxone sublingual tablets) in 2012 in the United States. However, from 2015 to 2020, the launches of novel therapies will drive market growth at an average annual rate of 5 percent.

“The uptake of two emerging agents will make the greatest contribution to the market—the launch of nalmefene in Europe in 2012 for alcohol dependence and the launch of the buprenorphine implant for opioid dependence in the United States in 2013 and in Europe in 2015,” said Decision Resources Principal Director of CNS Products, Andrea Witt, Ph.D.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Mental Health  Pharmaceutical  Other Health

MEDIA:

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.